PDCD1 and neoplasm: Data from literature suggested that soluble form of immune checkpoints such as sPD1, sPD-L1, sLAG-3, and sCTLA-4 levels can potentially serve as predictive biomarkers for anti-PD1 immunotherapy because they reflect the immunosuppressive tumor microenvironment and T cell dysfunction.